Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5686060	BRACCO	Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography	Nov, 2019 (4 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10232061	BRACCO	Freeze-dried formulation for gas-filled microvesicles	Jul, 2038 (14 years from now)
US10335502	BRACCO	Freeze-dried formulation for gas-filled microvesicles	Jul, 2038 (14 years from now)
US11723869	BRACCO	Freeze-dried product and gas-filled microvesicles suspension	May, 2039 (15 years from now)

Lumason is owned by Bracco.

Lumason contains Sulfur Hexafluoride Lipid-Type A Microspheres.

Lumason has a total of 4 drug patents out of which 1 drug patent has expired.

Expired drug patents of Lumason are:

Lumason was authorised for market use on 15 October, 2014.

Lumason is available in for suspension;intravenous dosage forms.

Lumason can be used as use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions.

Drug patent challenges can be filed against Lumason from 10 October, 2018.

The generics of Lumason are possible to be released after 15 May, 2039.

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-728)	Mar 31, 2019
New Chemical Entity Exclusivity(NCE)	Oct 10, 2019
New Patient Population(NPP)	Nov 13, 2022

NCE-1 date: 10 October, 2018

Market Authorisation Date: 15 October, 2014

Treatment: Use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions

Dosage: FOR SUSPENSION;INTRAVENOUS

Lumason patents expiration